The Buckle Hikes on Q2 Figures
The Buckle, Inc. (NYSE: BKE) announced today that net income for the fiscal quarter ended August 2, 2025 was $45.0 million, or $0.90 per share ($0.89 per share on a diluted basis).Net sales for the 13-week fiscal quarter increased 8.3 percent to $305.7 million from net sales of $282.4 million for the prior year 13-week fiscal quarter ended August 3, 2024. Comparable store net sales for the 13-week fiscal quarter ended August 2, 2025 increased 7.3% from comparable store net sales for the prior year 13-week period ended August 3, 2024. Online sales increased 17.7% to $43.6 million for the 13-week fiscal quarter ended August 2, 2025, compared to net sales of $37.0 million for the 13-week fiscal quarter ended August 3, 2024.Net sales for the 26-week fiscal period ended August 2, 2025 increased 6.1% to $577.9 million from net sales of $544.9 million for the prior year 26-week fiscal period ended August 3, 2024. Comparable store net sales for the 26-week period ended August 2, 2025 increased 5.2% from comparable store net sales for the prior year 26-week period ended August 3, 2024. Net income for the second quarter of fiscal 2025 was $45.0 million, or $0.90 per share ($0.89 per share on a diluted basis), compared with net income of $39.3 million, or $0.79 per share ($0.78 per share on a diluted basis) for the second quarter of fiscal 2024.BKE shares began Friday trade up 77 cents, or 1.4%, to $55.59.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


